Press Release

Implicity secures $40M growth equity funding to scale its AI-driven cardiac monitoring platform globally

The round is led by growth fund IRIS alongside Five Arrows. Funding will fuel Implicity’s next phase of growth in the US through local commercial hires, build on its established leadership across Europe, and accelerate further AI investment. Implicity already serves over 250 medical centers and monitors 120,000+ patients daily across the US, France, and Germany.

Cambridge, MA, USA and Paris, France — September 9, 2026

Cambridge, MA, USA and Paris, France, September 9, 2026 – Implicity, a global leader in AI-driven cardiac remote monitoring, has secured a $40 million funding round led by European tech growth capital firm IRIS, alongside Five Arrows, the alternative assets arm of Rothschild & Co.

Enabling clinicians to act on cardiac data at scale

Remote patient monitoring has become the standard of care in cardiology following the 2023 HRS/EHRA/APHRS/LAHRS Expert Consensus¹. Today, care teams manage more sources than ever, from cardiac implantable electronic devices to heart failure monitoring. While each new data stream provides valuable clinical insight, it also adds complexity for the clinicians piecing the full picture together. Too much time is spent navigating multiple systems and triaging alerts to identify events that require action. This administrative burden reduces time available for direct patient care, potentially delaying responses to the events that matter most.

Implicity helps to solve this with a single, AI-driven platform that aggregates, normalizes, and analyzes data across the full continuum, regardless of device manufacturer. It also integrates with EHRs to streamline providers’ workflow. By bringing every signal into one intelligent view, Implicity lets clinicians spend less time searching through the noise and more time on patient care.

“I didn’t become a physician to manage data — I became one to treat patients,” said Dr. Arnaud Rosier, electrophysiologist, CEO and co-founder of Implicity. “This funding lets us care for patients at scale, catching the information through the noise to provide the best possible care — and that’s the future of cardiology I’ve been chasing since my first year as an electrophysiologist.”

Dr. Arnaud Rosier, Electrophysiologist, CEO & Co-Founder of Implicity

Proven clinical impact and market traction

Unlike traditional remote monitoring solutions, Implicity has built deep clinical credibility through its FDA-cleared AI algorithms and extensive real-world evidence. Patients monitored with Implicity have seen 26% reduction in mortality and 4% reduction in hospitalizations², compared to those on conventional remote monitoring. SignalHF^†, Implicity’s heart failure prediction algorithm, gives clinicians early visibility into a patient’s heart failure risk to support earlier identification and intervention.³ The platform’s ECG Analyzer^‡ feature also reduces false alarms by up to 76%^4,5, so clinicians spend less time sorting through alerts and more time with the patients who need them most.

The fundraising will support Implicity’s next phase of growth in the US. The company has built its hospital network on the ground from its Cambridge, MA base, earning the endorsement of clinicians and forging partnerships with local physicians. The round will be used for commercial hiring to widen that footprint and the development of US-specific features for one of the world’s largest healthcare markets. It will also fund continued investment in the company’s AI and innovation roadmap — including the next generation of Heart Failure prediction algorithms — to better serve medical teams and optimize care for remotely monitored patients.

“In the evolving healthtech landscape, long-term success requires a rare combination of robust technology, strict regulatory clearance, and undeniable clinical utility. Implicity has proven to be a highly trusted partner to complex health systems because its platform directly addresses the administrative and operational crisis facing hospital workforces today. We are thrilled to back the team as they cement their leadership in the US market and drive the next phase of digital healthcare infrastructure.”

Nicolas Herschtel, Partner at IRIS’ Growth team

“Implicity is a rare company where clinical superiority, regulatory credibility and genuine patient impact come together at scale. By turning fragmented cardiac data into action, it improves outcomes for patients while relieving the operational pressure on hospital teams. This is precisely the kind of sustainable, mission-driven business we seek to support.”

François-Xavier Lehman, Director at Five Arrows

Press Release

Study shows Implicity’s new agnostic cloud-based AI algorithm further reduces false alerts even after manufacturer AI filtering in modern devices

New HRS data extends EHRA findings with a specific analysis of next-gen ILRs, demonstrating that, on top of manufacturer-embedded AI, Implicity filters out 61.6% of false positives while maintaining 98.3% sensitivity^*.

Cambridge, MA, USA — April 25, 2026

CAMBRIDGE, Mass., April 25, 2026 (GLOBE NEWSWIRE) -- Implicity, a leader in remote patient monitoring and cardiac data management solutions, today announced the latest findings presented at the Heart Rhythm Society (HRS) 2026.

The new HRS data extends on research presented earlier this month at the European Heart Rhythm Association (EHRA) Congress, which showed why false-positive alerts persist even in modern implantable loop recorders (ILRs). The follow-on HRS study specifically focused on the latest AI-equipped ILRs, examining whether layering Implicity’s new, universal cloud-based AI algorithm on top of proprietary manufacturer algorithms could further reduce false alerts.

In a review of 483 cases from 324 patients using AI-equipped devices, Implicity’s next-generation ILR ECG Analyzer successfully reclassified 61.6% of false-positive alerts in interpretable episodes while maintaining 98.3% sensitivity, helping reduce the workload for clinicians without compromising patient safety.

“Manufacturer filtering has clearly advanced, whether it happens in the device, in the cloud, or through a combination of both. But even in these newer systems, residual false-positive alerts still remain and continue to burden clinical teams. The findings from our HRS study demonstrate that a manufacturer-agnostic analysis layer can substantially reduce that remaining noise while maintaining the high sensitivity needed to protect patient safety,”

Arnaud Rosier, MD, PhD, electrophysiologist, CEO, and co-founder of Implicity

Implicity’s next-generation ILR ECG Analyzer is designed to act as an agnostic second-layer for residual alerts that remain after the initial manufacturer filters. Operating in the cloud and compatible with all major brands, Implicity’s new universal algorithm applies the most sophisticated neural networks, drastically reducing false positives without compromising patient safety.

This 'dual AI' approach does more than just streamline remote cardiac monitoring workflows; it also reduces alert fatigue by providing clinical teams with highly accurate, trustworthy data. With greater confidence in the data, clinicians can spend less time on noise and more time focusing on meaningful cardiac events.

“Newer AI-enabled ILRs do provide a cleaner data stream with fewer obvious artifacts, but they are not perfect, and the false positives that remain are often more subtle and clinically ambiguous. Those are exactly the alerts that still require careful adjudication. In a remote monitoring workflow, that matters enormously, and any technology that can safely mitigate ILR-related false-positive alerts is significant.”

Niraj Varma, MD, PhD, Professor of Medicine and Consultant Electrophysiologist at the Cleveland Clinic

These findings follow evidence presented at EHRA examining why false-positive alerts persist across modern ICM devices. In that work, investigators identified guideline-based interpretation gaps and signal-detection issues as key drivers of non-actionable alerts and showed that even in AI-equipped devices, 32.9% of episodes remained non-actionable, with another 30.6% deemed indeterminate. Together, the EHRA and HRS analyses highlight both the mechanisms behind persistent false positives and the potential for a universal, cloud-based AI approach to help address them across all devices—including those with or without proprietary AI.

Implicity’s next-generation ILR ECG Analyzer Algorithm (V2) is not FDA cleared yet.